The University of Chicago hypertension expert discusses new ADA recommendations for cardiovascular risk management.
Episode highlights
0:19 Intro 1:46 New ADA Guidelines 2:30 Introducing Dr. Bakris 3:25 The need for conservative guidelines 5:50 The cardiometabolic care collaboration 8:02 The trials that defined guidelines 11:50 How guideline decisions are made 15:30 The US - EU disparity in care 22:01 Navigating costly therapies 24:12 Introducing diet and exercise specialists 28:20 US healthcare’s hurdles in cardiovascular care 30:30 How COVID-19 influences the field 32:20 Wearable technology and telemedicine 34:26 Outro
The American Diabetes Association (ADA) recently published updated annual guidelines which provide clinicians perspective on diagnosing, screening, and managing hypertension and cardiovascular risks in patients with type 2 diabetes.
The guidelines, which feature collaborative perspective from the American College of Cardiology (ACC), serve as a point of reflection on all the various advances being made in treating comorbid cardiovascular risk among the growing diabetes population.
They also provide context on the comprehensive utility of drug classes such as GLP-1 agonists and SGLT-2 inhibitors, which have been increasingly investigated for various health outcomes in cardiometabolic patients for a decade now—and continue to be assessed for more benefits now.
There’s much to address in the single mention of the state of cardiometabolic care. The first DocTalk episode of the year aims to tackle all the facets of the new guidelines, and more.
In an interview with HCPLive, George Bakris, MD, professor of medicine and director of the Comprehensive Hypertension Center at the University of Chicago School of Medicine, shared perspective on the new ADA guidelines and trials which influenced it, the evolving cardiometabolic care team, and the current issues burdening the field at this moment.
